Back to Directory
Fibraxis
Birmingham
Founded 2024
Preclinical therapeutic company targeting tissue fibrosis in allergic asthma
Fibraxis is a preclinical-stage biotechnology company developing a therapeutic for allergic asthma that targets tissue fibrosis in the lung.
Spun out of Aston University and supported by SPARK The Midlands, the company builds on research into pericytes, the mesenchymal cells implicated in airway scarring and remodelling that occurs following chronic tissue damage.
Fibraxis aims to serve patients with allergic asthma and related chronic respiratory conditions caused by unresolved lung inflammation.